[Clinical practice guidelines for alpha-thalassemia]

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020 Mar 10;37(3):235-242. doi: 10.3760/cma.j.issn.1003-9406.2020.03.003.
[Article in Chinese]

Abstract

Alpha-thalassemia is an autosomal recessive genetic disease as well as a relatively common hemoglobinopathy. Severe alpha-thalassemia (also known as Hb Bart's Hydrops fetalis syndrome) and intermediate alpha-thalassemia (also known as Hb H disease) are among the most common birth defects in southern China. To implement carrier screening and large population prevention program in high incidence areas can significantly reduce the incidence of alpha-thalassemia. This guideline was established by combining the discoveries of basic research, clinical research and guidelines from other countries and the actual data of Chinese population. It has summarized the medical genetics knowledge and key points in the clinical treatment for alpha-thalassemia, and provided suggestions for the clinical diagnosis and standard management of patients.

MeSH terms

  • China
  • Genetics, Medical
  • Hemoglobins, Abnormal
  • Humans
  • Hydrops Fetalis / diagnosis*
  • Hydrops Fetalis / therapy*
  • Practice Guidelines as Topic*
  • alpha-Thalassemia / diagnosis*
  • alpha-Thalassemia / therapy*

Substances

  • Hemoglobins, Abnormal